AMAG Pharmaceuticals Inc
(NASDAQ: AMAG)
-0.30
-1.46%
| Exchange: | NASDAQ |
| Stock: | AMAG Pharmaceuticals, Inc. |
| Industry: | Diagnostic Substances |
| Employees: | 129 |
| AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The Company markets and sells Feraheme in the United States through its own commercial organization. Feraheme is approved for use in the treatment of both dialysis and non-dialysis dependent chronic kidney disease (CKD) patients. The Company’s principal source of revenue is from the sale of Feraheme (ferumoxytol) Injection for intravenous (IV). In December 2011, Feraheme was also granted marketing approval in Canada for use as an IV iron replacement therapy for the treatment of IDA in adult patients with CKD. GastroMARK, which is marketed and sold under the trade name Lumirem outside of the United States, is the Company’s oral contrast agent used for delineating the bowel in magnetic resonance imaging (MRI), and is approved and marketed in the United States, Europe, and other countries through its licensees. |
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.
